# DRUG QUANTITY MANAGEMENT POLICY - PER RX

#### POLICY:

Pulmonary – Corticosteroid/Long-Acting Beta<sub>2</sub>-Agonist Combination Inhalers Drug Quantity Management Policy – Per Rx

- Advair Diskus<sup>®</sup> (fluticasone propionate/salmeterol inhalation powder GlaxoSmithKline, generic [including Wixela Inhub<sup>®</sup>])
- Advair® HFA (fluticasone propionate/salmeterol inhalation aerosol GlaxoSmithKline)
- AirDuo<sup>®</sup> Digihaler<sup>™</sup> (fluticasone propionate/salmeterol inhalation powder Teva)
- AirDuo® RespiClick® (fluticasone propionate/salmeterol inhalation powder Teva, generic)
- Breo<sup>®</sup> Ellipta<sup>®</sup> (fluticasone furoate/vilanterol inhalation powder GlaxoSmithKline; generic)
- Dulera® (mometasone furoate/formoterol fumarate inhalation aerosol Merck)
- Symbicort® (budesonide/formoterol fumarate inhalation aerosol AstraZeneca, generic)

**REVIEW DATE:** 01/11/2023

## **OVERVIEW**

All of the inhaled corticosteroid (ICS) and long-acting beta<sub>2</sub>-agonist (LABA) combination inhalers are indicated for the **treatment of asthma**.<sup>1-7</sup> Breo Ellipta is indicated in patients  $\geq$  18 years of age; Advair HFA, AirDuo RespiClick, and AirDuo Digihaler are indicated in patients  $\geq$  12 years of age. Symbicort, Dulera, and Advair Diskus are indicated in patients  $\geq$  6 years of age,  $\geq$  5 years of age, and  $\geq$  4 years of age, respectively.

 Advair Diskus, Symbicort, and Breo Ellipta are also approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and to reduce COPD exacerbations.

## Dosing/Availability

Dosing and Availability of the ICS/LABA combination inhalers is in Table 1.

Table 1. Dosing and Availability of the ICS/LABA Combination Products. 1-7

Brand (generic)	Dosage	Available	Doses per Package	Asthma Dosing	COPD
	Form	Strength(s)			Dosing
Advair Diskus®	DPI	100/50 mcg	14 blisters/inhaler*	$\geq$ 12 years of age: one inhalation	One
(fluticasone			60 blisters/inhaler	BID (initial dose based on	inhalation
propionate/				asthma severity and previous	of 250/50
salmeterol		250/50 mcg	14 blisters/inhaler*	therapy).	mcg BID.
inhalation powder,		_	60 blisters/inhaler	Max dose: one inhalation of	
generic [including				500/50 mcg BID.	
Wixela Inhub])		500/50 mcg	14 blisters/inhaler*		
			60 blisters/inhaler	4 to 11 years of age: One	
				inhalation of 100/50 mcg BID.	
Advair® HFA	pMDI	45/21 mcg	60 inhalations/canister*	≥ 12 years of age: Two	NA
(fluticasone			120 inhalations/canister	inhalations BID (initial dose	
propionate/		115/21 mcg	60 inhalations/canister*	based on asthma severity and	
salmeterol			120 inhalations/canister	previous therapy)	
inhalation aerosol)		230/21 mcg	60 inhalations/canister*	Max dose: two inhalations of	
			120 inhalations/canister	230/21 mcg BID.	

Table 1 (continued). Dosing and Availability of the ICS/LABA Combination Products. 1-7

 $Pulmonary-Corticosteroid/Long-Acting\ Beta_2-Agonist\ Combination\ Inhalers\ DQM\ Policy-Per\ Rx\ Page\ 2$ 

Brand (generic)	Dosage Form	Available Strength(s)	Doses per Package	Asthma Dosing	COPD Dosing
AirDuo® Digihaler™ (fluticasone propionate/ salmeterol inhalation powder)	DPI w/ a built in electroni c module	55/14 mcg	60 actuations/canister	≥ 12 years of age: One inhalation BID (initial dose based on asthma severity and	NA
		113/14 mcg	60 actuations/canister	previous therapy)  • Max dose: One inhalation of	
		232/14 mcg	60 actuations/canister	232/14 mcg BID.	
AirDuo RespiClick® (fluticasone propionate/ salmeterol inhalation powder, authorized generic)	DPI	55/14 mcg	60 actuations/canister	≥ 12 years of age: One inhalation BID (initial dose based on asthma severity and	NA
		113/14 mcg	60 actuations/canister	previous therapy).  • Max dose: One inhalation	
		232/14 mcg	60 actuations/canister	of 232/14 mcg BID.	
Breo® Ellipta® (fluticasone furoate/ vilanterol inhalation powder, authorized generic)	DPI	100/25 mcg	14 inhalations (28 blisters)/canister* 30 inhalations (60 blisters)/canister	<ul> <li>18 years of age: One inhalation QD (initial dose based on asthma severity and previous therapy).</li> <li>Max dose: One inhalation of 200/25 mcg QD</li> </ul>	One inhalation of 100/25 mcg QD
		200/25 mcg	14 inhalations (28 blisters)/canister* 30 inhalations (60 blisters)/canister		
Dulera® (mometasone furoate/ formoterol fumarate inhalation aerosol)	pMDI	50/5 mcg	120 inhalations/canister	≥ 12 years of age: Two inhalations BID (initial dose based on asthma severity and	NA
		100/5 mcg	60 inhalations/canister* 120 inhalations/canister	previous therapy).  • Max dose: Two inhalations of 200/5 mcg BID.	
		200/5 mcg	60 inhalations/canister* 120 inhalations/canister	5 to < 12 years of age: Two inhalations BID of 50/5mcg.	
Symbicort® (budesonide/ formoterol fumarate inhalation aerosol, authorized generic)	pMDI	80/4.5 mcg	60 inhalations/canister* 120 inhalations/canister	≥ 12 years of age: Two inhalations BID (initial dose based on asthma severity and previous therapy).	Two inhalations of 160/4.5 mcg BID
		160/4.5 mcg	60 inhalations/canister* 120 inhalations/canister	Max dose: Two inhalations of 160/4.5 mcg BID.	meg DID
				≥ 6 years of age: Two inhalations of 80/4.5 mcg BID.	

ICS – Inhaled corticosteroid; LABA – Long-acting beta<sub>2</sub>-agonist; COPD – Chronic obstructive pulmonary disease; DPI – Drypowder inhaler; \* Institutional pack; BID – Twice daily; pMDI – Pressurized metered-dose inhaler; NA – Not applicable; QD – Once daily.

## **Guidelines**

The Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention (2022) recommends low-dose ICS/formoterol as the preferred initial asthma reliever therapy for the majority of symptomatic patients ≥ 12 years of age. In patients with more severe symptoms, a medium-dose ICS/formoterol is recommended to be used as both reliever and maintenance therapy. Of note, the two ICS/LABA combination inhalers containing and ICS with formoterol that are available in the US are Symbicort and Dulera, neither of which is FDA-approved to be dosed "as needed". However, the vast majority of the data to support this dosing is with Symbicort's active ingredients, budesonide and formoterol. Therefore, an exception is provided below for Symbicort for patients who are using it according to these guideline recommendations.

#### POLICY STATEMENT

 $Pulmonary-Corticosteroid/Long-Acting\ Beta_2-Agonist\ Combination\ Inhalers\ DQM\ Policy-Per\ Rx\ Page\ 3$ 

This Drug Quantity Management program has been developed to prevent stockpiling, misuse and/or overuse of the corticosteroid/long-acting beta<sub>2</sub>-agonist combination inhalers. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Automation: None.

**Drug Quantity Limits** 

Brand (generic)		Strength	Package Size(s)	Retail Maximum Quantity per Rx	Home Delivery Maximum Quantity per Rx
Advair Diskus® (fluticasone propionate/		100/50 mcg	14 blisters/inhaler*	1 inhaler	3 inhalers
			60 blisters/inhaler	1 inhaler	3 inhalers
	nhalation	250/50 mcg	14 blisters/inhaler*	1 inhaler	3 inhalers
powder,	generic		60 blisters/inhaler	1 inhaler	3 inhalers
[including Wixela		500/50 mcg	14 blisters/inhaler*	1 inhaler	3 inhalers
Inhub])			60 blisters/inhaler	1 inhaler	3 inhalers
Advair <sup>®</sup>	HFA	45/21 mcg	60 inhalations/canister (8 g)*	8 grams (1 inhaler)	24 grams (3 inhalers
	opionate/		120 inhalations/canister (12 g)	12 grams (1 inhaler)	36 grams (3 inhalers)
salmeterol in	inhalation	115/21 mcg	60 inhalations/canister (8 g)*	8 grams (1 inhaler)	24 grams (3 inhalers)
aerosol)			120 inhalations/canister (12 g)	12 grams (1 inhaler)	36 grams (3 inhalers)
		230/21 mcg	60 inhalations/canister (8 g)*	8 grams (1 inhaler)	24 grams (3 inhalers)
			120 inhalations/canister (12 g)	12 grams (1 inhaler)	36 grams (3 inhalers)
	igihaler™	55/14 mcg	60 actuations/canister	1 inhaler	3 inhalers
	opionate/	113/14 mcg	60 actuations/canister	1 inhaler	3 inhalers
salmeterol inhalation powder)		232/14 mcg	60 actuations/canister	1 inhaler	3 inhalers
	spiClick®	55/14 mcg	60 actuations/canister	1 inhaler	3 inhalers
	opionate/	113/14 mcg	60 actuations/canister	1 inhaler	3 inhalers
	nhalation uthorized	232/14 mcg	60 actuations/canister	1 inhaler	3 inhalers
Breo® (fluticasone	Ellipta® furoate/ inhalation authorized	100/25 mcg	14 inhalations (28 blisters)/canister*	28 blisters (1 inhaler)	84 blisters (3 inhalers)
powder, au			30 inhalations (60 blisters)/canister	60 blisters (1 inhaler)	180 blisters (3 inhalers)
generic)		200/25 mcg	14 inhalations (28 blisters)/canister*	28 blisters (1 inhaler)	84 blisters (3 inhalers)
			30 inhalations (60 blisters)/canister	60 blisters (1 inhaler)	180 blisters (3 inhalers)
	(mometasone formoterol inhalation	50/5 mcg	120 inhalations/canister (13 g)	1 inhaler (13 grams)	3 inhalers (39 grams)
		100/5 mcg	60 inhalations/canister (8.8g)*	1 inhaler (9 grams)	3 inhalers (27 grams)
			120 inhalations/canister (13 g)	1 inhaler (13 grams)	3 inhalers (39 grams)
aerosol)	ľ	200/5 mcg	60 inhalations/canister (8.8 g)*	1 inhaler (9 grams)	3 inhalers (27 grams)
		_	120 inhalations/canister (13 g)	1 inhaler (13 grams)	3 inhalers (39 grams)
Symbicort® (bud	lesonide/	80/4.5 mcg	60 inhalations/canister (6.9 g)*	7 grams (1 inhaler)	21 grams (3 inhalers)
	fumarate aerosol,	00, 110 11118	120 inhalations/canister (10.2 g)	11 grams (1 inhaler)	31 grams (3 inhalers)
authorized gener		160/4.5	60 inhalations/canister (6 g)*	6 grams (1 inhaler)	18 grams (3 inhalers)
Č	•	mcg	120 inhalations/canister (10.2 g)	11 grams (1 inhaler)	31 grams (3 inhalers)

<sup>\*</sup> Institutional pack.

## **CRITERIA**

Pulmonary – Corticosteroid/Long-Acting Beta<sub>2</sub>-Agonist Combination Inhalers DQM Policy – Per Rx Page 4

## Budesonide/formoterol 80/4.5 mcg and 160/4.5 mcg inhalation aerosol (Symbicort, authorized generic)

1. If the patient has asthma and is using budesonide/formoterol (Symbicort, authorized generic) as a reliever therapy, approve the requested quantity not to exceed 2 inhalers per dispensing at retail or 4 inhalers per dispensing at home delivery.

All other corticosteroid/long-acting beta<sub>2</sub>-agonist combination inhalers No overrides recommended.

#### REFERENCES

- 1. Advair Diskus® inhalation powder [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; January 2019.
- 2. Advair® HFA inhalation aerosol [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2021.
- 3. Symbicort® inhalation aerosol [prescribing information]. Wilmington, DE: AstraZeneca; December 2017.
- 4. Dulera® inhalation aerosol [prescribing information]. Whitehouse Station, NJ: Merck; August 2019.
- 5. Breo<sup>®</sup> Ellipta<sup>®</sup> inhalation powder [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; January 2019.
- 6. AirDuo® RespiClick® inhalation powder [prescribing information]. Frazer, PA: Teva Respiratory; July 2021.
- 7. AirDuo® Digihaler® inhalation powder [prescribing information]. Frazer, PA: Teva Respiratory; July 2021.
- 8. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2022. Accessed on December 28, 2022. Available at: <a href="http://www.ginasthma.org">http://www.ginasthma.org</a>.